Medimmune Biotech arm of Astrazeneca got around $ 150 Million from US government for Swine flu treatment therapy out of which $ 90 million was for development of swine flu vaccine. Already reports state that AstraZeneca is testing the nasal-spray technology FluMist for a product which will help to tackle swine flu, also known as the H1N1 virus. This spray FluMist generated around $ 104 Million sales last year and it is expected to generate $ 2 to 2.5 Billion by 2009-2010. According to scientists the Advantage of FLuMist is that it contains weakened forms of a live virus thus may require a much lower dose to build up immunity. Astra spoke person said that it is sooner going to start the clinical trial for Nasal spray for H1N1 treatment.
Friday, August 21, 2009
H1N1 Therapy Part 2....................
Medimmune Biotech arm of Astrazeneca got around $ 150 Million from US government for Swine flu treatment therapy out of which $ 90 million was for development of swine flu vaccine. Already reports state that AstraZeneca is testing the nasal-spray technology FluMist for a product which will help to tackle swine flu, also known as the H1N1 virus. This spray FluMist generated around $ 104 Million sales last year and it is expected to generate $ 2 to 2.5 Billion by 2009-2010. According to scientists the Advantage of FLuMist is that it contains weakened forms of a live virus thus may require a much lower dose to build up immunity. Astra spoke person said that it is sooner going to start the clinical trial for Nasal spray for H1N1 treatment.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment